Eliminating the Shadow of Cancer
Watch Etira’s WEBINAR
Eliminating the Shadow of Cancer
How many times have we heard the dreaded news that the cancer has returned or progressed to widespread metastatic disease in a loved one, a colleague or friend? The prognosis is often bleak, and despite best available treatments, life expectancy is often measured in weeks and months.
Why cannot treatments overcome cancer? The seemingly insurmountable barrier is the “tumor heterogeneity”, or the genetic variability of cancer. This means that while some cancer cells within a tumor may be sensitive to a treatment there are other cancer cells within the same tumor that are resistant and will continue to grow, these ‘therapy resistant’ cells soon become dominant and the tumor regrows rapidly. There are currently no approved targeted therapies for therapy resistant tumors, the patient’s current options are highly toxic chemotherapy if they can tolerate, clinical trials for investigational drugs or palliative care.
In July 2022 Etira’s scientific team published a paper detailing the discovery of a new molecular target for cancer therapy and the exploitation of a fundamental weakness in cancer cells, Endoplasmic Reticulum Stress (ER Stress) that took the scientific world by storm.
ERX-315’s paradigm shift in cancer therapy detailed a method of overcoming tumor heterogeneity and therapy resistance by inducing toxic levels of ER Stress in cancer cells regardless of genetic background, effectively treating a vast majority of cells in a tumor not just the dominant cells as is the case with current therapies. Most importantly ERX-315 while highly toxic to cancer cells and killing them, leaves normal cells intact.
The unique cancer specific qualities of ERX-315 opens the pathway for wide utility as either a monotherapy or in combination with standard of care therapies. A potential pan-cancer drug, ERX-315 has already proven efficacy in mouse models with metastatic breast, liver, ovarian, endometrial and pancreatic cancers, furthermore Etira’s scientists expect it to be also efficacious with many more cancer indications.
In Q3 2024 Etira’s breakthrough drug ERX-315 is headed to much anticipated Clinical Trials with therapy resistant cancer patients, if successful ERX-315 will be the first single therapy to effectively treat therapy resistance and overcome tumor heterogeneity, providing hope for over 260,000 patients in the US alone that have no other treatment options, while paving a new path forward in cancer therapy.
To learn more please contact Spotlight Family Office Group at Info@SpotlightFamilyOffice.com.